Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (31-40 of 791) with videos related to

Pageof 80
Sort By:
Blood Advances|October 11, 2024
Tyrosine kinase inhibitor for CML: all the same?Lukas Veltmaat, Jorge Cortes
Cancer|May 13, 2004
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disordersJorge Cortes, Hagop Kantarjian
Seminars in Hematology|February 4, 2003
Advanced-phase chronic myeloid leukemiaJorge Cortes, Hagop Kantarjian
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemiaJorge Cortes, Hagop Kantarjian
Blood|May 23, 2012
How I treat newly diagnosed chronic phase CMLJorge Cortes, Hagop Kantarjian
Journal of Hematology & Oncology|March 19, 2021
Third-line therapy for chronic myeloid leukemia: current status and future directionsJorge Cortes, Fabian Lang
Haematologica|April 27, 2023
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?Sandeep Padala, Jorge Cortes
Current Opinion in Hematology|January 27, 2007
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phaseEhab Atallah, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|September 25, 2009
New agents in chronic myelogenous leukemiaJorge Cortes, Francis Giles
Blood|January 9, 2024
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitorsLukas Veltmaat, Jorge Cortes
Pageof 80

Showing results (31-40 of 791) with videos related to

Sort By:
Pageof 80
Blood Advances|October 11, 2024
Tyrosine kinase inhibitor for CML: all the same?Lukas Veltmaat, Jorge Cortes
Cancer|May 13, 2004
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disordersJorge Cortes, Hagop Kantarjian
Seminars in Hematology|February 4, 2003
Advanced-phase chronic myeloid leukemiaJorge Cortes, Hagop Kantarjian
Journal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemiaJorge Cortes, Hagop Kantarjian
Blood|May 23, 2012
How I treat newly diagnosed chronic phase CMLJorge Cortes, Hagop Kantarjian
Journal of Hematology & Oncology|March 19, 2021
Third-line therapy for chronic myeloid leukemia: current status and future directionsJorge Cortes, Fabian Lang
Haematologica|April 27, 2023
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?Sandeep Padala, Jorge Cortes
Current Opinion in Hematology|January 27, 2007
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phaseEhab Atallah, Jorge Cortes
Journal of the National Comprehensive Cancer Network : JNCCN|September 25, 2009
New agents in chronic myelogenous leukemiaJorge Cortes, Francis Giles
Blood|January 9, 2024
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitorsLukas Veltmaat, Jorge Cortes
Pageof 80